These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

270 related items for PubMed ID: 32493344

  • 1. Linagliptin, when compared to placebo, improves CD34+ve endothelial progenitor cells in type 2 diabetes subjects with chronic kidney disease taking metformin and/or insulin: a randomized controlled trial.
    Awal HB, Nandula SR, Domingues CC, Dore FJ, Kundu N, Brichacek B, Fakhri M, Elzarki A, Ahmadi N, Safai S, Fosso M, Amdur RL, Sen S.
    Cardiovasc Diabetol; 2020 Jun 03; 19(1):72. PubMed ID: 32493344
    [Abstract] [Full Text] [Related]

  • 2. Role of Canagliflozin on function of CD34+ve endothelial progenitor cells (EPC) in patients with type 2 diabetes.
    Nandula SR, Kundu N, Awal HB, Brichacek B, Fakhri M, Aimalla N, Elzarki A, Amdur RL, Sen S.
    Cardiovasc Diabetol; 2021 Feb 13; 20(1):44. PubMed ID: 33581737
    [Abstract] [Full Text] [Related]

  • 3. The synergistic effects of saxagliptin and metformin on CD34+ endothelial progenitor cells in early type 2 diabetes patients: a randomized clinical trial.
    Dore FJ, Domingues CC, Ahmadi N, Kundu N, Kropotova Y, Houston S, Rouphael C, Mammadova A, Witkin L, Khiyami A, Amdur RL, Sen S.
    Cardiovasc Diabetol; 2018 May 03; 17(1):65. PubMed ID: 29724198
    [Abstract] [Full Text] [Related]

  • 4. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk.
    Rosenstock J, Perkovic V, Alexander JH, Cooper ME, Marx N, Pencina MJ, Toto RD, Wanner C, Zinman B, Baanstra D, Pfarr E, Mattheus M, Broedl UC, Woerle HJ, George JT, von Eynatten M, McGuire DK, CARMELINA® investigators.
    Cardiovasc Diabetol; 2018 Mar 14; 17(1):39. PubMed ID: 29540217
    [Abstract] [Full Text] [Related]

  • 5. A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes.
    Jax T, Stirban A, Terjung A, Esmaeili H, Berk A, Thiemann S, Chilton R, von Eynatten M, Marx N.
    Cardiovasc Diabetol; 2017 Jan 21; 16(1):13. PubMed ID: 28109295
    [Abstract] [Full Text] [Related]

  • 6. Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine.
    Ott C, Jung S, Korn M, Kannenkeril D, Bosch A, Kolwelter J, Striepe K, Bramlage P, Schiffer M, Schmieder RE.
    Cardiovasc Diabetol; 2021 Sep 04; 20(1):178. PubMed ID: 34481498
    [Abstract] [Full Text] [Related]

  • 7. Combination of the dipeptidyl peptidase-4 inhibitor linagliptin with insulin-based regimens in type 2 diabetes and chronic kidney disease.
    McGill JB, Yki-Järvinen H, Crowe S, Woerle HJ, von Eynatten M.
    Diab Vasc Dis Res; 2015 Jul 04; 12(4):249-57. PubMed ID: 25941160
    [Abstract] [Full Text] [Related]

  • 8. [The efficacy and safety of linagliptin in elderly patients with type 2 diabetes: a pooled analysis of eight placebo-controlled clinical trials].
    Guo XH, Feng ZK, Xu LH.
    Zhonghua Nei Ke Za Zhi; 2017 Aug 01; 56(8):588-594. PubMed ID: 28789492
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of linagliptin in Asian patients with type 2 diabetes mellitus inadequately controlled by metformin: A multinational 24-week, randomized clinical trial.
    Wang W, Yang J, Yang G, Gong Y, Patel S, Zhang C, Izumoto T, Ning G.
    J Diabetes; 2016 Mar 01; 8(2):229-37. PubMed ID: 25753488
    [Abstract] [Full Text] [Related]

  • 10. Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study.
    Han SY, Yoon SA, Han BG, Kim SG, Jo YI, Jeong KH, Oh KH, Park HC, Park SH, Kang SW, Na KR, Kang SW, Kim NH, Jang Y, Kim B, Shin S, Cha DR.
    Diabetes Obes Metab; 2018 Feb 01; 20(2):292-300. PubMed ID: 28719008
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of linagliptin in subjects with type 2 diabetes mellitus and poor glycemic control: pooled analysis of data from three placebo-controlled phase III trials.
    Del Prato S, Taskinen MR, Owens DR, von Eynatten M, Emser A, Gong Y, Chiavetta S, Patel S, Woerle HJ.
    J Diabetes Complications; 2013 Feb 01; 27(3):274-9. PubMed ID: 23403068
    [Abstract] [Full Text] [Related]

  • 12. Effects of linagliptin on endothelial function and postprandial lipids in coronary artery disease patients with early diabetes: a randomized, placebo-controlled, double-blind trial.
    Tripolt NJ, Aberer F, Riedl R, Url J, Dimsity G, Meinitzer A, Stojakovic T, Aziz F, Hödl R, Brachtl G, Strunk D, Brodmann M, Hafner F, Sourij H.
    Cardiovasc Diabetol; 2018 May 17; 17(1):71. PubMed ID: 29773079
    [Abstract] [Full Text] [Related]

  • 13. DPP-4 inhibition has no acute effect on BNP and its N-terminal pro-hormone measured by commercial immune-assays. A randomized cross-over trial in patients with type 2 diabetes.
    Fadini GP, Bonora BM, Albiero M, Zaninotto M, Plebani M, Avogaro A.
    Cardiovasc Diabetol; 2017 Feb 10; 16(1):22. PubMed ID: 28183314
    [Abstract] [Full Text] [Related]

  • 14. Acute Effects of Linagliptin on Progenitor Cells, Monocyte Phenotypes, and Soluble Mediators in Type 2 Diabetes.
    Fadini GP, Bonora BM, Cappellari R, Menegazzo L, Vedovato M, Iori E, Marescotti MC, Albiero M, Avogaro A.
    J Clin Endocrinol Metab; 2016 Feb 10; 101(2):748-56. PubMed ID: 26695864
    [Abstract] [Full Text] [Related]

  • 15. Linagliptin plus metformin in patients with newly diagnosed type 2 diabetes and marked hyperglycemia.
    Ross SA, Caballero AE, Del Prato S, Gallwitz B, Lewis-D'Agostino D, Bailes Z, Thiemann S, Patel S, Woerle HJ, von Eynatten M.
    Postgrad Med; 2016 Nov 10; 128(8):747-754. PubMed ID: 27684308
    [Abstract] [Full Text] [Related]

  • 16. How are patients with type 2 diabetes and renal disease monitored and managed? Insights from the observational OREDIA study.
    Penfornis A, Blicklé JF, Fiquet B, Quéré S, Dejager S.
    Vasc Health Risk Manag; 2014 Nov 10; 10():341-52. PubMed ID: 24966684
    [Abstract] [Full Text] [Related]

  • 17. Effect of linagliptin on pulse wave velocity in early type 2 diabetes: A randomized, double-blind, controlled 26-week trial (RELEASE).
    de Boer SA, Heerspink HJL, Juárez Orozco LE, van Roon AM, Kamphuisen PW, Smit AJ, Slart RHJA, Lefrandt JD, Mulder DJ.
    Diabetes Obes Metab; 2017 Aug 10; 19(8):1147-1154. PubMed ID: 28244635
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of linagliptin in subjects with long-standing type 2 diabetes mellitus (>10 years): evidence from pooled data of randomized, double-blind, placebo-controlled, phase III trials.
    Lajara R, Aguilar R, Hehnke U, Woerle HJ, von Eynatten M.
    Clin Ther; 2014 Nov 01; 36(11):1595-605. PubMed ID: 25236917
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis.
    Zinman B, Ahrén B, Neubacher D, Patel S, Woerle HJ, Johansen OE.
    Can J Diabetes; 2016 Feb 01; 40(1):50-7. PubMed ID: 26474870
    [Abstract] [Full Text] [Related]

  • 20. Metformin improves circulating endothelial cells and endothelial progenitor cells in type 1 diabetes: MERIT study.
    Ahmed FW, Rider R, Glanville M, Narayanan K, Razvi S, Weaver JU.
    Cardiovasc Diabetol; 2016 Aug 26; 15(1):116. PubMed ID: 27561827
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.